CalquenceActive Ingredient(s): Acalabrutinib
FDA Approved: * October 31, 2017
Pharm Company: * ACERTA PHARMA BV
Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings. Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. It is a second genera... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.